These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7762722)

  • 21. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 22. Estimating the burden of serogroup C meningococcal disease in England and Wales.
    Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
    Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal vaccine: new recommendations for immunization of college freshmen.
    Baltimore RS; Jenson HB
    Curr Opin Pediatr; 2001 Feb; 13(1):47-50. PubMed ID: 11176243
    [No Abstract]   [Full Text] [Related]  

  • 25. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; Erickson L
    Vaccine; 2002 Jun; 20(21-22):2840-4. PubMed ID: 12102036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding Factors Affecting University A Students' Decision to Receive an Unlicensed Serogroup B Meningococcal Vaccine.
    Breakwell L; Vogt TM; Fleming D; Ferris M; Briere E; Cohn A; Liang JL
    J Adolesc Health; 2016 Oct; 59(4):457-64. PubMed ID: 27523976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
    Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
    Welte R; Trotter CL; Edmunds WJ; Postma MJ; Beutels P
    Pharmacoeconomics; 2005; 23(9):855-74. PubMed ID: 16153131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for meningococcal disease in college students.
    Bruce MG; Rosenstein NE; Capparella JM; Shutt KA; Perkins BA; Collins M
    JAMA; 2001 Aug; 286(6):688-93. PubMed ID: 11495618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.
    Christensen H; Trotter CL
    Vaccine; 2017 Jan; 35(2):208-211. PubMed ID: 27923519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
    BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing meningococcal infection in college students.
    Harrison LH
    Clin Infect Dis; 2000 Apr; 30(4):648-51. PubMed ID: 10770724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Meningococcal C conjugate vaccine: Impact of a vaccination program and long-term effectiveness in Navarra, Spain, 2000-2014].
    Morales D; García-Cenoz M; Moreno L; Bernaola E; Barricarte A; Castilla J
    Enferm Infecc Microbiol Clin; 2016 Dec; 34(10):639-644. PubMed ID: 26778101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P; Deceuninck G; Boulianne N; De Serres G
    JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.
    Fijen CA; Kuijper EJ; Drogari-Apiranthitou M; Van Leeuwen Y; Daha MR; Dankert J
    Clin Exp Immunol; 1998 Dec; 114(3):362-9. PubMed ID: 9844044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.